A Real-world Study on the Incidence and Outcome of Immune-related Adverse Events in Lung Cancer Patients.
10.3779/j.issn.1009-3419.2023.101.08
- Author:
Shaohua CUI
1
;
Xiaoxiao GE
1
;
Xiangyang LI
1
Author Information
1. Department of Respiratory and Critical Care Medicine, Huadong Hospital, Fudan University, Shanghai 200040, China.
- Publication Type:Journal Article
- Keywords:
Immune-related adverse events;
Immunotherapy;
Lung neoplasms;
Survival time
- MeSH:
Humans;
Lung Neoplasms;
Carcinoma, Non-Small-Cell Lung/drug therapy*;
Immune Checkpoint Inhibitors/therapeutic use*;
Incidence;
Antineoplastic Agents, Immunological/therapeutic use*;
Drug-Related Side Effects and Adverse Reactions/drug therapy*;
Retrospective Studies
- From:
Chinese Journal of Lung Cancer
2023;26(4):257-264
- CountryChina
- Language:Chinese
-
Abstract:
BACKGROUND:Immune-related adverse events (irAEs) are commonly occurred in patients treated with immune checkpoint inhibitors. However, evidence of irAEs derived from the Chinese population is relatively lacking. The aim of this study was to investigate the incidence and outcomes of irAEs in Chinese patients with lung cancer after receiving immune checkpoint inhibitors (ICIs).
METHODS:Clinical and follow-up data from lung cancer patients who received at least one time of ICIs from January 2018 to September 2021 at Huadong Hospital, Fudan University were included. Statistical descriptions and Kaplan-Meier method were used to analyze the overall incidence of irAEs, as well as the incidence and outcomes of each type of irAEs.
RESULTS:135 patients were included in the study. 106 patients (78.5%) presented at least one type of irAEs, and the median time to first irAEs onset was 28 d. Most irAEs occurred at early time after treatment, and most irAEs were mild-moderate and reversible. 57 patients (42.2%) died at the study cutoff. The mortality rate of severe irAEs was 12.6% (n=17), and among them 7 patients (41.2%) died of pneumonitis. The median progression-free survival (PFS) and overall survival (OS) time of the total population was 505 d (95%CI: 352-658) and 625 d (95%CI: 491-759), respectively. Patients who presented any irAEs achieved a longer PFS than those who did not (median PFS: 533 d vs 179 d, P=0.037, HR=0.57), while patients who presented skin toxicities achieved a longer OS than patients who did not (median OS: 797 d vs 469 d, P=0.006, HR=0.70).
CONCLUSIONS:In real-world settings, irAEs in lung cancer patients were commonly observed, with pneumonitis as the most common fatal irAEs. In addition, patients who presented any irAEs may tend to achieve a longer PFS.
